“COMPARISON OF 10% POTASSIUM HYDROXIDE (KOH) SOLUTION V/S 5% IMIQUIMOD CREAM V/S ORAL RANITIDINE IN THE TREATMENT OF MOLLUSCUM CONTAGIOSUM”

Main Article Content

Dr. Sankalp Awasthi
Dr. Manisha Nijhawan
Dr. Kiran Kumawat
Dr. Meet Patel

Keywords

5% imiquimod, 10% potassium hydroxide, Molluscum contagiosum, Oral ranitidine, children, immunomodulatory

Abstract

Context: The majority of treatment options in molluscum contagiosum traumatise the lesions and must be performed in a hospital, making patients anxious.
Aims: This study aims at comparing 10% potassium hydroxide (KOH) solution, 5% imiquimod cream and oral ranitidine in the treatment of MC in search for an alternative therapy.
Settings and Design: The study was carried out at a tertiary care hospital in the Department of Dermatology, Venereology and Leprosy, Jaipur, Rajasthan, India, from January 2021 to September 2022; with triple group cohorts.
Methods and Material: Patients having atleast three MC lesions aged between 5-54 years were enrolled in the study and were allocated into three groups, A, B, and C, each with 30 patients. Group A patients were instructed to apply the 10% KOH solution, group B received 0.25 g sachets of 5% imiquimod cream and group C received oral ranitidine at a dose of 5 mg/kg/day in two divided doses for eight weeks.
Statistical analysis used: To compare the groups of data, ANOVA test was used.
Results: At the end of this study, complete clearance of lesions was seen in 36% (9/25) patients in group A, 33.33% (7/25) patients in Group B and 15.80% (3/19) patients in group C. 48% (12/25) patients in Group A showed adverse effects in contrast to Group B with only 50% (6/12) patients showing adverse effects. No adverse events were reported among the patients in Group C.
Conclusions: It would seem reasonable to use 10% KOH solution because it is effective and affordable, albeit with a few minor side effects.

Abstract 107 | pdf Downloads 48

References

1. Dohil MA, Lin P, Lee J, Lucky AW, Paller AS, Eichenfield LF. The epidemiology of Molluscum contagiosum in children. J Am Acad Dermatol 2006;54:47-54.
2. van der Wouden JC, van der Sande R, van Suijlekom-Smit LW, Berger M, Butler CC, Koning S. Interventions for cutaneous Molluscum contagiosum. Cochrane Database Syst Rev 2009 oct 7;(4):CD004767.
3. Mathes EF, Frieden IJ. Treatment of Molluscum contagiosum with cantharidin: A practical approach. Pediatr Ann 2010;39:124-8, 130.
4. Berger EM, Orlow SJ, Patel RR, Schaffer JV. Experience with Molluscum contagiosum and associated inflammatory reactions in a pediatric dermatology practice: The bump that rashes. Arch Dermatol 2012;148:1257-64.
5. Romiti R, RibeiroAP, Grinblat BM, Rivitti EA, Romiti N. Treatment of Molluscum contagiosum with potassium hydroxide: Aclinical approach in 35 children. Pediatr Dermatol 1999;16:228-31.
6. Hengge UR, Esser S, Schultewolter T, Behrendt C, Meyer T, Stockfleth E, et al. Self-administered topical 5% imiquimod for the treatment of common warts and Molluscum contagiosum. Br J Dermatol 2000;143:1026-31.
7. Short KA, Fuller LC, Higgins EM. Double-blind, randomized, placebo-controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of Molluscum contagiosum. Pediatr Dermatol 2006;23:279-81.
8. Lacarrubba F, Nasca MR, Micali G. Advances in the use of topical imiquimod to treat dermatologic disorders. Ther Clin Risk Manag 2008;4:87-97.
9. Mavligit GM, Talpaz M. Cimetidine for herpes zoster. N Engl J Med 1984;310:318-9.
10. Bayerl C, Feller G, Goerdt S. Experience in treating Molluscum contagiosum in children with imiquimod 5% cream. Br J Dermatol 2003;149 Suppl 66:25-9.
11. Arany I, Tyring SK. Activation of local cell mediated immunity in interferon responsive patients with human papillomavirus-associated lesions. J Interferon Cytokine Res 1996;16:453-60.
12. Spradbrow PB. Immune response to papillomaviruses infection. In: Syrj‰nen K, Gissmann L, Koss LG, editors. Papillomaviruses and human disease. Berlin: Springer-Verlag, 1987. p. 334-70.
13. Dawson J, Richards DA, Stables R, Dixon GT, Cockel R. Ranitidine – Pharmacology and clinical use. J Clin Hosp Pharm 1983;8:1-3.
14. Brogden RN, CarmineAA, Heel RC, Speight TM, Avery GS. Ranitidine: A review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1982;24:267-303.
15. Pahwa R, Shilpa Sharma S, Kumar V, Kohli K. Ranitidine hydrochloride: An update on analytical, clinical and pharmacological aspects. J Chem Pharm Res 2016;8:70-8.
16. Seo SH, Chin HW, Jeong DW, Sung HW. An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of Molluscum contagiosum. Ann Dermatol 2010;22:156-62.
17. MetkarA, Pande S, Khopkar U. An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of Molluscum contagiosum. Indian J Dermatol Venereol Leprol 2008;74:614-8.
18. Mahajan BB, Pall A, Gupta RR. Topical 20% KOH – An effective therapeutic modality for Molluscum contagiosum in children. Indian J Dermatol Venereol Leprol 2003;69:175-7.
19. Puri N. A study on the use of imiquimod for the treatment of genital Molluscum contagiosum and genital warts in female patients. Indian J Sex Transm Dis 2009;30:84-8